Evidence for the Use of Epoprostenol to Treat Raynaud’s Phenomenon With or Without Digital Ulcers

Cruz, Joseph E.; Ward, Ashley V.; Anthony, Shannon; Chang, Shih-Shin; Bae, Hyun Billy; Hermes-DeSantis, Evelyn R.

doi:10.1177/1060028016660324

Cited by 20 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33,50 Prostanoid therapy (eg iloprost or epoprostenol) is administered (intravenously) in cases of refractory digital ulcers (to foster ulcer healing and reduce new ulceration) and is also used in patients with severe RP (despite the previously described interventions). [51][52][53] The endothelin-receptor antagonist bosentan is licensed in Europe for the treatment of digital ulcers in SSc. Bosentan reduces the development of new ulcers but does not impact on the healing of existing ulcers.…”

Section: Drug Therapy For Refractory Rpmentioning

confidence: 99%

Raynaud's phenomenon

Haque

Hughes

2020

Clinical Medicine

View full text Add to dashboard Cite

Section: Drug Therapy For Refractory Rpmentioning

confidence: 99%

Raynaud's phenomenon

Haque

Hughes

2020

Clinical Medicine

View full text Add to dashboard Cite

“…Intravenous therapy with prostacyclin analogues is well established in the treatment of patients in whom RP is very severe and has progressed to digital ulceration. Most experience is with iloprost but epoprostenol 57 may also be used. Intravenous prostanoids reduce frequency and severity of RP attacks and heal digital ulcers.…”

Section: Treatment Of Rp Which Has Progressed To Digital Ulceration Omentioning

confidence: 99%

Evidence-based management of Raynaud’s phenomenon

Herrick

2017

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Raynaud's phenomenon (RP) is relevant to the rheumatologist because it may signify an underlying connective tissue disease and also because it can be very challenging to treat, especially when it has progressed to digital ulceration or critical ischaemia. This review article discusses diagnosis (does this patient have an underlying connective tissue disease?), including the role for nailfold capillaroscopy, and treatment. Management of 'uncomplicated' RP is first described and then treatment of RP complicated by progression to digital ulceration or critical ischaemia, highlighting recent advances (including phosphodiesterase type 5 inhibition, and endothelin 1 receptor antagonism) and the evidence base underpinning these. Possible future therapies are briefly discussed.

show abstract

“…69,70 Prescribing practice varies internationally: IV iloprost has been most studied and is most widely used, and in varying regimes, 71 but is not available in the United States, IV epoprostenol is another option. 72 Cruz et al 73 have recently reviewed the use of IV epoprostenol. A major disadvantage of IV prostanoids is the need for hospitalisation, as well as systemic vasodilatory side-effects.…”

Section: Treatment Of Complicated Rp (Digital Ulceration and Criticalmentioning

confidence: 99%

Raynaud’s phenomenon

Herrick

2019

Journal of Scleroderma and Related Disorders

View full text Add to dashboard Cite

Raynaud's phenomenon can be either primary (idiopathic) or secondary to underlying disease including systemic sclerosis. Primary Raynaud's phenomenon is very common, affecting approximately 3%-5% of the general population. Although much rarer, systemic sclerosis-related Raynaud's phenomenon can be particularly severe, progressing to digital ulceration in approximately 50% of patients. Raynaud's phenomenon can have a major impact on quality of life. This review has a focus on the systemic sclerosis-related Raynaud's phenomenon (which is the most researched form of Raynaud's phenomenon and probably the most challenging to treat) and on recent advances. Epidemiology (including transition from 'isolated' to systemic sclerosis-related Raynaud's phenomenon), pathogenesis, diagnosis and assessment are discussed, followed by the treatment of both 'uncomplicated' and 'complicated' Raynaud's phenomena (i.e. Raynaud's phenomenon which has progressed to digital ulceration and/or critical ischaemia). Finally, some of the major challenges for the next 5-10 years are highlighted.

show abstract

Evidence for the Use of Epoprostenol to Treat Raynaud’s Phenomenon With or Without Digital Ulcers

Cited by 20 publications

References 33 publications

Raynaud's phenomenon

Raynaud's phenomenon

Evidence-based management of Raynaud’s phenomenon

Raynaud’s phenomenon

Contact Info

Product

Resources

About